A phase 2 study of KOS-862 administered intravenously weekly for 3 weeks every 4 weeks, in patients with hormone resistant prostate cancer who have progressed following initial therapy for metastatic disease

Trial Profile

A phase 2 study of KOS-862 administered intravenously weekly for 3 weeks every 4 weeks, in patients with hormone resistant prostate cancer who have progressed following initial therapy for metastatic disease

Discontinued
Phase of Trial: Phase II

Latest Information Update: 16 Sep 2008

At a glance

  • Drugs Epothilone D (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 16 Sep 2008 Sponsor and collaborator changed from Kosan Biosciences to Bristol-Myers Squibb according to ClinicalTrials.gov.
    • 01 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top